日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program

人工智能预测丙型肝炎病毒患者直接抗病毒药物治疗失败:一项全国性丙型肝炎病毒登记计划

Lu, Ming-Ying; Huang, Chung-Feng; Hung, Chao-Hung; Tai, Chi-Ming; Mo, Lein-Ray; Kuo, Hsing-Tao; Tseng, Kuo-Chih; Lo, Ching-Chu; Bair, Ming-Jong; Wang, Szu-Jen; Huang, Jee-Fu; Yeh, Ming-Lun; Chen, Chun-Ting; Tsai, Ming-Chang; Huang, Chien-Wei; Lee, Pei-Lun; Yang, Tzeng-Hue; Huang, Yi-Hsiang; Chong, Lee-Won; Chen, Chien-Lin; Yang, Chi-Chieh; Yang, Sheng-Shun; Cheng, Pin-Nan; Hsieh, Tsai-Yuan; Hu, Jui-Ting; Wu, Wen-Chih; Cheng, Chien-Yu; Chen, Guei-Ying; Zhou, Guo-Xiong; Tsai, Wei-Lun; Kao, Chien-Neng; Lin, Chih-Lang; Wang, Chia-Chi; Lin, Ta-Ya; Lin, Chih-Lin; Su, Wei-Wen; Lee, Tzong-Hsi; Chang, Te-Sheng; Liu, Chun-Jen; Dai, Chia-Yen; Kao, Jia-Horng; Lin, Han-Chieh; Chuang, Wan-Long; Peng, Cheng-Yuan; Tsai, Chun-Wei-; Chen, Chi-Yi; Yu, Ming-Lung

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

口服 FGFR、VEGFR 和 PDGFR 抑制剂多韦替尼 (TKI258) 治疗晚期或转移性肾细胞癌的 I 期研究

Eric Angevin, Jose A Lopez-Martin, Chia-Chi Lin, Jürgen E Gschwend, Andrea Harzstark, Daniel Castellano, Jean-Charles Soria, Paramita Sen, Julie Chang, Michael Shi, Andrea Kay, Bernard Escudier

Acrylamide, an air pollutant, enhances allergen-induced eosinophilic lung inflammation via group 2 innate lymphoid cells

空气污染物丙烯酰胺通过第 2 组先天淋巴细胞增强过敏原诱发的嗜酸性肺部炎症

Hsiang-Han Su, Chih-Mei Cheng, Yung-Ning Yang, Yu-Wei Chang, Chia-Yang Li, Shin-Ting Wu, Chia-Chi Lin, Hsin-En Wu, Jau-Ling Suen

An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan

基于台湾全国数据的简化丙型肝炎病毒治疗算法(无需专科医生诊治)

Yu, Ming-Lung; Tai, Chi-Ming; Mo, Lein-Ray; Kuo, Hsing-Tao; Huang, Chung-Feng; Tseng, Kuo-Chih; Lo, Ching-Chu; Bair, Ming-Jong; Wang, Szu-Jen; Huang, Jee-Fu; Yeh, Ming-Lun; Chen, Chun-Ting; Tsai, Ming-Chang; Huang, Chien-Wei; Lee, Pei-Lun; Yang, Tzeng-Hue; Huang, Yi-Hsiang; Chong, Lee-Won; Chen, Chien-Lin; Yang, Chi-Chieh; Hung, Chao-Hung; Yang, Sheng-Shun; Cheng, Pin-Nan; Hsieh, Tsai-Yuan; Hu, Jui-Ting; Wu, Wen-Chih; Cheng, Chien-Yu; Chen, Guei-Ying; Zhou, Guo-Xiong; Tsai, Wei-Lun; Kao, Chien-Neng; Lin, Chih-Lang; Wang, Chia-Chi; Lin, Ta-Ya; Lin, Chih-Lin; Su, Wei-Wen; Lee, Tzong-Hsi; Chang, Te-Sheng; Liu, Chun-Jen; Dai, Chia-Yen; Chen, Chi-Yi; Kao, Jia-Horng; Lin, Han-Chieh; Chuang, Wan-Long; Peng, Cheng-Yuan

Vaccine optimization for highly pathogenic avian influenza: Assessment of antibody responses and protection for virus-like particle vaccines in chickens

高致病性禽流感疫苗优化:评估病毒样颗粒疫苗在鸡体内的抗体反应和保护效果

Ku, Chia-Chi; Lin, Cheng-Yu; Yang, Chin-Rur; Yang, Yu-Chih; Chen, Po-Ling; Lin, Yi-Te; Wang, Pei-Ru; Lee, Min-Shi; Liang, Shu-Mei; Hsiao, Pei-Wen

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer

IGF 中和抗体 xentuzumab 与恩杂鲁胺治疗转移性去势抵抗性前列腺癌的 Ib/II 期研究

Valentine M Macaulay, Simon Lord, Syed Hussain, José Pablo Maroto, Robert Hugh Jones, Miguel Ángel Climent, Natalie Cook, Chia-Chi Lin, Shian-Shiang Wang, Diletta Bianchini, Mark Bailey, Laura Schlieker, Thomas Bogenrieder, Johann de Bono

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

FGF401 以及 FGF401 与 spartalizumab 联合治疗肝细胞癌或生物标志物选定的实体瘤患者的首次人体 1/2 期研究

Stephen L Chan, Martin Schuler, Yoon-Koo Kang, Chia-Jui Yen, Julien Edeline, Su Pin Choo, Chia-Chi Lin, Takuji Okusaka, Karl-Heinz Weiss, Teresa Macarulla, Stéphane Cattan, Jean-Frederic Blanc, Kyung-Hun Lee, Michela Maur, Shubham Pant, Masatoshi Kudo, Eric Assenat, Andrew X Zhu, Thomas Yau, Ho Yeon

Podcasts, the pandemic, and a paradigm shift in medical careers

播客、疫情与医疗职业的范式转变

Chu, Cheng-Feng; Chang, Chia-Chi; Lin, Yu-Hsuan

Specific inactivation of an antifungal bacterial siderophore by a fungal plant pathogen

真菌植物病原体特异性灭活抗真菌细菌铁载体。

Ho, Ying-Ning; Hoo, Sin Yong; Wang, Bo-Wei; Hsieh, Chi-Ting; Lin, Ching-Chih; Sun, Chi-Hui; Peng, Chia-Chi; Lin, Chih; Yang, Yu-Liang

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors

抗 PD-1 抗体 Spartalizumab (PDR001) 在晚期实体瘤患者中开展的首次人体 1 期剂量递增研究

Aung Naing, Justin F Gainor, Hans Gelderblom, Patrick M Forde, Marcus O Butler, Chia-Chi Lin, Sunil Sharma, Maria Ochoa de Olza, Andrea Varga, Matthew Taylor, Jan H M Schellens, Hongqian Wu, Haiying Sun, Antonio P Silva, Jason Faris, Jennifer Mataraza, Scott Cameron, Todd M Bauer6